Citadel Advisors
PALI icon

Citadel Advisors’s Palisade Bio PALI Stock Holding History

Citadel Advisors’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Hold
0
– -$3K – 7610
2016
Q2 		– Hold
0
– – – 6757
2016
Q1 		– Hold
0
– – – 6612
2015
Q4 		– Hold
0
– – – 8620
2015
Q3 		– Hold
0
– – – 8125
2015
Q2 		– Hold
0
– – – 7831
2015
Q1 		– Hold
0
– – – 7447
2014
Q4 		– Hold
0
– – – 6631
2014
Q3 		– Hold
0
– – – 6607
2014
Q2 		– Hold
0
– – – 7313
2014
Q1 		– Hold
0
– – – 7312

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Citadel Advisors's PALI Position: Q1 2026 in Review

Citadel Advisors reduced its Palisade Bio (PALI) stake by 99% in Q1 2026, selling an estimated $3.07M and leaving 14,272 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #12624.

Citadel Advisors first reported a position in PALI in Q4 2018 and has held it in 10 quarters since. The position peaked at $4M in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • Citadel Advisors held 14,272 shares of Palisade Bio worth $25K as of Q1 2026.
  • Citadel Advisors sold 1,687,139 Palisade Bio shares in Q1 2026, an estimated $3.07M.
  • Palisade Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12624 holding.
  • Citadel Advisors first reported a position in Palisade Bio in Q4 2018 and has held it in 10 quarters since.
  • Citadel Advisors's Palisade Bio position peaked at $4M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.